Xuegui Cui – Trademark Portfolio

Entity Type: 01

Xuegui Cui holds 9 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 25 (Clothing) — 8 filings in this category. The portfolio also extends into Class 24 (Fabrics) across 2 Nice Classification classes. Currently, 9 trademarks are registered. Notable registered marks include MAVRO, ZYVON, CRIXOR, FLORINA, and HIKECOZ. The owner is based in Chongqing.

3-1, Unit 6, No. 216,

Nanshan Middle Rd., Hanfeng, Kai County,

Chongqing 405000 , CN

9 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

ZYVON
ZYVON
Registered 2024
FLORINA
FLORINA
Registered 2024
CRIXOR
CRIXOR
Registered 2024
MAVRO
MAVRO
Registered 2024
WARMLUXE
WARMLUXE
Registered 2023
HEATTREAD
HEATTREAD
Registered 2023
HIKECOZ
HIKECOZ
Registered 2023
SNUGGLOX
SNUGGLOX
Registered 2023

Trademark Classifications

Xuegui Cui's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

25
Clothing (8 filings)

Clothing, footwear, headgear

24
Fabrics (1 filing)

Textiles and textile goods; bed covers; table covers

Frequently Asked Questions

How many trademarks does Xuegui Cui have?

Xuegui Cui has 9 U.S. trademarks filed with the USPTO. Of these, 9 registered.

What trademark classes does Xuegui Cui file in?

Xuegui Cui files trademarks across 2 Nice Classification classes. The most active classes are Class 25 (Clothing), Class 24 (Fabrics). Class 25 covers clothing, footwear, headgear.

What are Xuegui Cui's most well-known trademarks?

Xuegui Cui's registered trademark portfolio includes well-known marks such as MAVRO, ZYVON, CRIXOR, FLORINA, and HIKECOZ. These are among 9 currently registered trademarks in the portfolio.

What is Xuegui Cui's trademark registration success rate?

Xuegui Cui has a 100% trademark registration rate, with 9 out of 9 resolved applications resulting in successful registration. Currently, 0 applications are pending review.